To determine the longitudinal development of drug use in very old adults. DESIGN: Longitudinal cohort study with waves in 1998, 2000, 2002, and 2005. SETTING: Nationwide study in Denmark. PARTICIPANTS: All living Danes born in 1905 were approached in 1998; 2,262 responded at baseline. MEASUREMENTS: Self-reported use of regularly taken drugs. Mean and median number of drugs and growth curve models were used to identify the change in number of drugs as the cohort aged from 92 to 100. RESULTS: The within-person use of drugs increased with age for women (0.19 per year; 95% confidence interval (CI) = 0.15-0.24) and men (0.15 per year; 95% CI = 0.06-0.24). Persons leaving the study prematurely had higher baseline values and a steeper increase in their annual use of drugs. The population-level mean number of drugs increased from baseline (3.6 drugs) to the first follow-up (4.1 drugs) but thereafter remained stable at approximately 4 drugs. Women used more drugs than men at all waves. CONCLUSION: In this first longitudinal study of drug use in nonagenarians, individuals used an increasing number of drugs as they aged. This increase is difficult to detect in cross-sectional analyses of the population-level mean. More efforts to understand what is reasonable prescribing at these older ages are needed. J Am Geriatr Soc 65: 160-164, 2017. 
T he prescription of drugs is the most common treatment for health problems at older ages, 1 and after age 80, more than half of remaining life can be expected to be spent with polypharmacy, 2 but little is known about the longitudinal development of drug use at these older ages.
Longitudinal studies of "younger old" populations suggest that the number of drugs used increases with age, with an increase estimated of between 0.04 and 0.48 drugs annually. [3] [4] [5] [6] [7] [8] [9] Nonagenarians' longitudinal pattern of drug use may be different from that of younger older adults, because cross-sectional data indicate that the number of drugs used increases from middle-age to old age but tends to stagnate or decrease after approximately 90 years of age. [10] [11] [12] [13] [14] Furthermore, women tend to use more drugs then men, 7, 15 although the sex difference seems to decline in very old age. 14 Two hypotheses have been proposed to explain why nonagenarians' drug use does not increase with age in cross-sectional studies. One suggestion is that prescribers deliberately avoid polypharmacy and are disinclined to start new therapies as frailer individuals approach death, because physiological changes make older people more sensitive to drugs. 16 Alternatively, it can be due to a healthy survivor effect. This would mean that individuals with poorer health using many drugs have higher mortality and thus successively leave the cohort as they die, generating a sample of more-robust individuals with lower drug use.
It was hypothesized that individual-level drug use would continue to increase in nonagenarians, to this end the Danish 1905 cohort was followed over seven years. Population-level means and medians of number of drugs used were compared with within-person change in number of drugs used as individuals aged from 92 to 100 years.
METHODS

Study Population
The Danish 1905 cohort was first contacted in 1998 and reassessed in 2000, 2003, and 2005 (aged 92/93-99/100).
All Danes born in 1905, regardless of living situation (institution or community) or health, were contacted for the study (n = 3,600). The response rate at the first contact in 1998 was 63% (n = 2,262) and in the latter surveys between 74% and 78%. 17 Approximately 10% did not respond to the question about drug use at each wave (item nonresponse); the study population was restricted to respondents with information on drug use at baseline (n = 1,988). Proxy interviews, with a relative or caregiver, were performed if respondents were unable to participate by themselves. A more-comprehensive description of the cohort is available elsewhere. 18, 19 A flowchart of the 1905 cohort is depicted in Figure 1 .
Drug use was assessed according to self-reported information on regularly used drugs at each wave. Respondents were asked to present a list or show their drug storage to avoid recall bias. The number of drugs used was calculated, including prescription and over-the-counter drugs but excluding all alternative drugs and vitamins. All drugs were coded according to the Anatomical Therapeutic Classification system as recommended by the World Health Organization. 20 Polypharmacy was classified as the concomitant use of five or more drugs. 21 
Statistical Analysis
Unweighted mean and median numbers of drugs are presented in Table 1 . Multilevel growth curve models were developed to study within-person changes in drug use over time (Table 1) . Time was introduced as number of years from baseline to reflect annual change in drug use. Higherlevel polynomials were tested but improved the fit of the model only marginally. Models were developed separately for the attrition groups leaving the study at different waves. Ordinary linear regression was performed to estimate the general population-level change in number of drugs used. Number of drugs used is a nonnormally distributed variable, so residual plots were used to assess whether the normality assumption of the residuals was fulfilled.
Adjustment for dropout (and item nonresponse) was implemented using inverse probability weighting for within-person and population-level changes. Weights were not applied for loss to follow-up because of death, because weighting for mortality will entail making inferences about an "immortal population." 22 Inverse probability weighting adjusts for dropouts by weighting the person's response at each wave for the inverse of the probability of participation for an individual having the same number of drugs as that person at the previous wave. The inverse probability weighting was based on number of drugs, and used as described previously. 22 All results are presented separately for women and men.
RESULTS
At baseline, 1,998 persons aged 92/93 had information about drug use, only 7% (n = 146) of these were still participating in the last wave of the survey. The proportion of women in the study population increased from 75% (n = 1,483) at baseline to 84% (n = 123) at last follow-up.
Approximately 18% (n = 361) were interviewed via proxy, and 27% (n = 545) were living in an institution at baseline. Proxy respondents used fewer drugs than nonproxy respondents at baseline. Individuals living in institutions used more drugs than those living in the community. In the total sample, 34% were on polypharmacy at baseline and 40% at the last follow-up (not shown). Figure 2 illustrates the mean number of drugs used at each wave (solid lines) and the previous means for all respondents in Waves 2, 3, and 4 (dashed lines). In the complete sample, the mean number of drugs increased from baseline (3.6 drugs) to the first follow-up but remained stable at approximately 4 drugs thereafter. Women used more drugs than men at all waves of the survey. For women, the mean number of drugs increased from baseline (3.7 drugs) to 4.3 drugs at age 100. For men, the mean number of drugs also increased initially and thereafter declined to be lower at age 100 (3.0 drugs) than at baseline (3.4 drugs). All respondents from Waves 2, 3, and 4 (dashed lines) increased their use of drugs from baseline, albeit with a lower mean number of drugs than the population mean at the previous waves. The only response group that did not show a clear increase in its use of drugs from baseline was men responding up to the last follow-up of the survey. The medians presented in Table 1 show similar patterns.
The annual within-person change in mean drug use when all cohort members were included was 0.21 for women and 0.24 for men (Table 1) . Women surviving to the last survey also experienced a within-person increase in the number of drugs (b = 0.18). For the surviving men, the regression estimate was also positive, but the confidence intervals included 0. Earlier exit from the study seem to be associated with a steeper annual increase in drugs used, although confidence intervals were mostly overlapping.
Women increased their population-level drug use by 0.10 drugs annually, whereas drug use by men did not change over time. Applying inverse probability weighting for dropouts had a negligible effect on population means and change over time.
As a sensitivity analysis, the analyses were rerun without baseline proxy respondents. When excluding proxy respondents, the mean use of drugs was higher at baseline, but the within-persons estimate changed only slightly (second decimal for the regression estimates) (not shown).
DISCUSSION
This is, to the knowledge of the authors, the first longitudinal study of drug use in nonagenarians; a nationwide cohort of Danes was followed as they aged from 92/93 to 99/100. Both men and women experienced a within-person increase in their use of drugs at these older ages. Participants exiting the study prematurely because of dropout or death used more drugs at baseline and tended to have a faster increase in their use of drugs. When considering only the population-level means at each wave, the increase was attenuated. These results suggest that individual drug use continues to increase in nonagenarians and that this is difficult to capture in cross-sectional studies of drug use.
In line with the hypothesis that nonagenarians would use an increasing number of drugs as they aged, a withinperson increase was found of 0.21 drugs annually for women and 0.24 for men. This confirms earlier longitudinal studies of drug use in samples of younger older adults suggesting an increase of 0.04-0.48 drugs annually. [3] [4] [5] [6] [7] [8] [9] It is likely that the stagnation or decrease in drug use of nonagenarians often found in cross-sectional studies [10] [11] [12] [13] [14] (similar to the current results for the population-level mean) is because of a healthy survivor effect; as the extensive drug users leave the cohort, the population means level off or decrease. At these older ages, the decrease in drug use due to selective mortality and dropout of the extensive drug users is large enough to offset the individual-level increase in drug use that the less-extensive drug users experience. Similar results have been found for independence, disability, depression, and physical and cognitive function in studies of nonagenarians. 17, 23 The groups leaving the study prematurely had a steeper annual increase in their use of drugs and higher baseline levels of drug use, which indicates that drug consumption is increasing when people are approaching death. Thus, little support was found that a more-palliative approach to prescribing is taking place in this cohort if this would entail the practice of deprescribing and an inclination to reduce polypharmacy at the end of life. 16 The only subgroup that did not experience increased use of drugs on the population or within-person level was men surviving to the last follow-up. The results of that specific subgroup should be regarded with caution because of the small sample size, but other longitudinal studies have also identified subgroups of men who do not seem to have an age increase in poor health at very old ages. 24, 25 Women used more drugs than men, which is in line with earlier research, 14, 15 although less is known about sex differences in the longitudinal development of drug use in older women and men. Both women and men experienced an increase in the number of drugs used on an individual level.
The main strength of this study was that a complete nationwide cohort of nonagenarians was followed, including people living in institutions and those who were cognitively impaired. As in all longitudinal studies of the older population, many people were lost to follow-up because of dropout and death. The main reason for loss to follow-up in this study was death. Inverse probability weighting used to adjust for dropout yielded only minor changes in the results. A potential limitation with the study is the selfreported measure of drug use. For this cohort, it has been validated that self-reported drug use yields a slightly smaller number of drugs than extracting the information from the Danish Prescription Medicine Registry, 26 although it is unclear whether the lower use of drugs according to self-report is due to underreporting or secondary nonadherence. Some evidence suggests that proxy respondents tend to underreport drug use, 27 and proxy respondents had lower drug use than self-respondents at baseline in the current study; a sensitivity analysis performed without the proxy respondents at baseline did not lead to a substantial change in the results. Thus, the analysis is presented including the proxy respondents to keep the nationwide cohort intact. Approximately 10% of the respondents did not report their drug use at each wave. The reason for nonresponse for this item is unknown, and it is unclear how this might have affected the results. Over time, people are using more drugs in most countries; 28, 29 the increasing number of drugs used in this study may be partly because of period effects. Given that drug use patterns are time and country specific, the current results might not be directly generalizable to other countries with different healthcare systems and to different time periods.
In sum, nonagenarians use an increasing number of drugs as they age on an individual level. Whether it is good clinical practice to increase drug use after 90 can be debated. Although an increase in drug use suggests that drug treatment is regularly updated, but greater sensitivity to drugs also leads to greater risk of unwanted consequences with advancing age. Future studies should investigate which drugs are introduced and what mechanisms lead to greater use of drugs, also at very old ages.
